About LAM Therapeutics
LAM Therapeutics was founded in 2013 with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. Working with a dedicated team of scientific, clinical, and drug development experts, LAM Therapeutics expects to use its disease-specific focus and technological approach to identify and advance drugs that will provide significant therapeutic benefit for LAM patients. LAM Therapeutics develops drugs for rare diseases and cancer. LAM takes advantage of the inflection point in biological understanding and computer science, leveraging big data from Next Gen sequencing, genome editing, chemical genomics, and combinational drug screening, to develop precision therapeutics and companion diagnostics. LAM has advanced two drugs into the clinic: LAM-001 for lymphangioleiomyomatosis, and LAM-002 for B-cell non-Hodgkin lymphoma.
|
|
|
1-10 employees
View all LAM Therapeutics employees
|
|
IT Services and IT Consulting
|
|
(203)458-7100
|
|
Guilford, Connecticut
|
|
2013
|
LAM Therapeutics Alternatives
Frequently Asked Questions about LAM Therapeutics
The decision makers in LAM Therapeutics are Jonathan Rothberg, etc. Click to Find LAM Therapeutics decision makers emails.
LAM Therapeutics Staff Directory
Search LAM Therapeutics Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
